Feng Zhu

List of Publications by Year
in descending order

13 papers	975 citations

933447

10 h-index	13 g-index

1125743

13 all docs	13 docs citations	13 times ranked	1714 citing authors

#	ARTICLE	IF	CITATIONS
1	Metagenome-wide association of gut microbiomeÂfeatures for schizophrenia. Nature Communications, 2020, 11, 1612.	12.8	204
2	Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. Cancer Cell, 2018, 33, 137-150.e5.	16.8	175
3	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. Gastroenterology, 2016, 151, 637-650.e10.	1.3	127
4	Identification of Stem Cells in the Epithelium of the Stomach Corpus and Antrum of Mice. Gastroenterology, 2017, 152, 218-231.e14.	1.3	121
5	Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity. Cell Reports, 2015, 12, 272-285.	6.4	112
6	Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut, 2021, 70, 829-837.	12.1	94
7	Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). Gut, 2022, 71, 854-863.	12.1	57
8	Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men. Emerging Microbes and Infections, 2021, 10, 2141-2150.	6.5	20
9	Mucosal microbiome associates with progression to gastric cancer. Theranostics, 2022, 12, 48-58.	10.0	17
10	Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: a cohort study. BMC Gastroenterology, 2009, 9, 76.	2.0	16
11	Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis. Value in Health, 2020, 23, 1171-1179.	0.3	15
12	DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia. Gut, 2020, 69, 1738-1749.	12.1	11
13	Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut, 2023, 72, 226-241.	12.1	6